Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify the source of chronic low back pain, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY (Chronic Low back pain Randomized Independent Trial studY) trial. Based in Beverly Hills, the private practice is known for expertise in complex spinal procedures and early adoption of advanced technologies. This inclusion represents the first private practice site in the 300-patient prospective, randomized, multi-center study evaluating Nociscan in patients undergoing surgical treatment for discogenic low back pain.
“I have spent more than 25 years practicing spinal surgery in Beverly Hills, and my perspective is shaped not only by that experience, but also by having undergone multiple spine surgeries myself,” said Todd Lanman, MD, neurosurgeon and founder of Lanman Spinal Neurosurgery. “We have made significant progress in moving beyond one-size-fits-all solutions for low back pain, driven by advances in technology and technique. Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs. This ability to match the right procedure to the right patient is what moves the field forward.”
The CLARITY trial’s primary endpoint is change in back pain on a 100mm VAS at 12 months compared to baseline, with several secondary endpoints. Aclarion anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026. Ryan Bond, Chief Strategy Officer of Aclarion, noted, “Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice. Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care, and we are excited to partner with his team as we continue to expand CLARITY and generate the high-quality evidence needed to advance Nociscan.”
Chronic low back pain affects approximately 266 million people worldwide. Aclarion’s Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain. The technology demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. For more information about the trial, visit CLARITY Trial. To find a Nociscan center, view the site map here.
